Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Department of Defense Appropriations Act, 2017
Client: ZYNERBA PHARMACEUTICALS · Firm: THE CONAFAY GROUP, LLC
H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.
Department of Defense Appropriations Act, 2017
Client: ZYNERBA PHARMACEUTICALS · Firm: THE CONAFAY GROUP, LLC
H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| REALTA LIFE SCIENCES, INC. | 10 | 2024–2026 |
| Xeris Pharmaceuticals, Inc. | 10 | 2019–2023 |
| CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) | 9 | 2021–2023 |
| EMERGEX VACCINES HOLDING LTD. | 9 | 2020–2022 |
| MIND MEDICINE INC. | 9 | 2024–2026 |
| INTERNATIONAL RETT SYNDROME FOUNDATION | 8 | 2024–2025 |
| SECURING AMERICAS MEDICINES AND SUPPLY SAMS | 8 | 2022–2023 |
| AGENUS INC. | 7 | 2017–2019 |
| ROIVANT SCIENCES, INC. | 7 | 2020–2021 |
| THE COALITION FOR ACCESS TO PRENATAL SCREENING | 7 | 2018–2023 |
| ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 6 | 2025–2026 |
| CHIESI USA INC | 5 | 2018 |
| NEURAL ANALYTICS | 5 | 2018–2019 |
| PULMOTECT, INC. | 5 | 2016–2017 |
| ZYNERBA PHARMACEUTICALS | 5 | 2016 |
| CHILD GENETIC SCREENING ALLIANCE | 4 | 2026 |
| CIDARA THERAPEUTICS INC | 4 | 2020 |
| PREACTIVE TECHNOLOGIES, INC. | 4 | 2020 |
| ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE | 4 | 2024 |
| TROIA THERAPEUTICS INC. | 4 | 2016 |
| UNITED STATES PHARMACOPEIAL CONVENTION | 4 | 2020 |
| ANI PHARMACEUTICALS | 3 | 2022 |
| CRESILON, INC. | 3 | 2026 |
| KIRIN BIOMATERIALS | 3 | 2026 |
| MID-ATLANTIC BIOTHERAPEUTICS | 3 | 2017 |
| PHLOW CORPORATION | 3 | 2020 |
| ATEA PHARMACEUTICALS, INC. | 2 | 2022 |
| KARYOPHARM THERAPEUTICS | 2 | 2017 |
| DOVA PHARMACEUTICALS | 1 | 2018 |
| SPECGX, LLC | 1 | 2020 |
Department of Defense Appropriations Act, 2017
Client: ZYNERBA PHARMACEUTICALS · Firm: THE CONAFAY GROUP, LLC
H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.
Department of Defense Appropriations Act, 2017
Client: ZYNERBA PHARMACEUTICALS · Firm: THE CONAFAY GROUP, LLC
H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.
2026 · third_quarter · Q3
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for the manufacture of bulk pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CRESILON, INC. via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for hemostatic technology research and the manufacturing of hemostatic products.
Support for hemostatic technology research and the manufacturing of hemostatic products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2026 · third_quarter · Q3
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for the manufacture of bulk pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CRESILON, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for hemostatic technology research and the manufacturing of hemostatic products.
Support for hemostatic technology research and the manufacturing of hemostatic products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2026 · second_quarter · Q2
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIRIN BIOMATERIALS via THE CONAFAY GROUP, LLC
2026 · second_quarter · RR
Support for the manufacture of bulk pharmaceuticals.
CRESILON, INC. via THE CONAFAY GROUP, LLC
2026 · second_quarter · RR
Support for hemostatic technology research and the manufacturing of hemostatic products.
Support for hemostatic technology research and the manufacturing of hemostatic products.
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Support for Genetic Screening.
Support for Genetic Screening.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Support for novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHILD GENETIC SCREENING ALLIANCE via THE CONAFAY GROUP, LLC
2026 · first_quarter · RR
Support for Genetic Screening.
Support for Genetic Screening.
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · 4T
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Patient access to novel HIE therapeutics.
Support for novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2025 · third_quarter · 3T
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · 2A
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · 1A
Patient access to novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Patient access to novel HIE therapeutics.
Patient access to novel HIE therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Education and advocacy for novel brain health treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REALTA LIFE SCIENCES, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Advocating for patient access to novel HIE therapeutics.
Advocating for patient access to novel HIE therapeutics.
MIND MEDICINE, INC. via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · RR
Education and advocacy for novel brain health treatments.
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Medicare and Medicaid Reform.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for biomedical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for biomedical research.
Support for biomedical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE via THE CONAFAY GROUP, LLC
2024 · second_quarter · RR
Increased funding for medical research.
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support research for Rett syndrome and rare diseases.
Support research for Rett syndrome and rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Pharmaceutical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL RETT SYNDROME FOUNDATION via THE CONAFAY GROUP, LLC
2024 · first_quarter · RR
Advocacy and education about Rett Syndrome. Seek funding for research for Rett Syndrome.
Advocacy and education about Rett Syndrome. Seek funding for research for Rett Syndrome.
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Medicare and Medicaid Reform.
Pharmaceutical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE COALITION FOR ACCESS TO PRENATAL SCREENING via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for access to prenatal testing.
Filing targets: HOUSE OF REPRESENTATIVES
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Pharmaceutical research.
Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for trauma research.
Support for trauma research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for vaccination technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XERIS PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for glucagon rescue therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Pharmaceutical research/Medicare and Medicaid Reform.
Pharmaceutical research/Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) via THE CONAFAY GROUP, LLC
2023 · second_quarter · 2T
Federal support to advance medical research.
Federal support to advance medical research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Research on vaccine technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XERIS PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Support for glucagon rescue therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Support for trauma research.
Support for trauma research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Support for a national TBI registry.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXXAS INC via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Research on vaccine technology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XERIS PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Support for glucagon rescue therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS INC. via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Pharmaceutical research/Medicare and Medicaid Reform.
Pharmaceutical research/Medicare and Medicaid Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Support for trauma research.
Support for trauma research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Federal support to advance medical research.
Federal support to advance medical research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2022 · first_quarter · RA
Advocate for national registry for individuals with traumatic brain injury.
VAXXAS INC via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Support for vaccine research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XERIS PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Support for Glucagon rescue therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL TBI REGISTRY COALITION via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Advocate for national registry for individuals with traumatic brain injuries.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SECURING AMERICAS MEDICINES AND SUPPLY SAMS via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Strengthening the medical supply chain.
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Support for trauma research.
Support for trauma research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Federal support to advance medical research.
Federal support to advance medical research
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE